NASDAQ:INBX - Inhibrx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.67
  • Forecasted Upside: 89.85 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$18.26
▼ -0.22 (-1.19%)
1 month | 3 months | 12 months
Get New Inhibrx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INBX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$34.67
▲ +89.85% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Inhibrx in the last 3 months. The average price target is $34.67, with a high forecast of $44.00 and a low forecast of $30.00. The average price target represents a 89.85% upside from the last price of $18.26.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Inhibrx.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/3/2021Credit Suisse GroupBoost Price Target$28.00 ➝ $44.00Low
i
10/15/2020Lifesci CapitalReiterated RatingOutperformMedium
i
Rating by A. Evertts at Lifesci Capital
9/14/2020Jefferies Financial GroupInitiated CoverageBuy$30.00High
i
9/14/2020Evercore ISIInitiated CoverageOutperform$30.00High
i
9/14/2020Credit Suisse GroupInitiated CoverageOutperform$26.00High
i
(Data available from 4/21/2016 forward)
Inhibrx logo
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $18.26
$17.13
$18.42

50 Day Range

MA: $21.73
$16.27
$29.75

52 Week Range

Now: $18.26
$15.20
$50.97

Volume

88,832 shs

Average Volume

145,063 shs

Market Capitalization

$689.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Inhibrx?

The following Wall Street research analysts have issued reports on Inhibrx in the last twelve months: Credit Suisse Group AG, Evercore ISI, Jefferies Financial Group Inc., Lifesci Capital, and Zacks Investment Research.
View the latest analyst ratings for INBX.

What is the current price target for Inhibrx?

3 Wall Street analysts have set twelve-month price targets for Inhibrx in the last year. Their average twelve-month price target is $34.67, suggesting a possible upside of 89.9%. Credit Suisse Group AG has the highest price target set, predicting INBX will reach $44.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $30.00 for Inhibrx in the next year.
View the latest price targets for INBX.

What is the current consensus analyst rating for Inhibrx?

Inhibrx currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INBX will outperform the market and that investors should add to their positions of Inhibrx.
View the latest ratings for INBX.

What other companies compete with Inhibrx?

How do I contact Inhibrx's investor relations team?

Inhibrx's physical mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The company's listed phone number is 858-795-4220 and its investor relations email address is [email protected] The official website for Inhibrx is www.inhibrx.com.